

# EP35

## Assessment of Equivalence or Suitability of Specimen Types for Medical Laboratory Measurement Procedures

This guideline provides recommendations for assessing clinically equivalent performance for additional similar-matrix specimen types and suitable performance for dissimilar-matrix specimen types, such that the laboratory does not necessarily need to repeat the full measurement procedure validation for each specimen type. The recommendations in this guideline apply to both quantitative measurement procedures and qualitative examinations.

.....  
A guideline for global application developed through the Clinical and Laboratory Standards Institute consensus process.

# Clinical and Laboratory Standards Institute

*Setting the standard for quality in medical laboratory testing around the world.*

The Clinical and Laboratory Standards Institute (CLSI) is a not-for-profit membership organization that brings together the varied perspectives and expertise of the worldwide laboratory community for the advancement of a common cause: to foster excellence in laboratory medicine by developing and implementing medical laboratory standards and guidelines that help laboratories fulfill their responsibilities with efficiency, effectiveness, and global applicability.

## Consensus Process

Consensus—the substantial agreement by materially affected, competent, and interested parties—is core to the development of all CLSI documents. It does not always connote unanimous agreement but does mean that the participants in the development of a consensus document have considered and resolved all relevant objections and accept the resulting agreement.

## Commenting on Documents

CLSI documents undergo periodic evaluation and modification to keep pace with advances in technologies, procedures, methods, and protocols affecting the laboratory or health care.

CLSI's consensus process depends on experts who volunteer to serve as contributing authors and/or as participants in the reviewing and commenting process. At the end of each comment period, the committee that developed the document is obligated to review all comments, respond in writing to all substantive comments, and revise the draft document as appropriate.

Comments on published CLSI documents are equally essential and may be submitted by anyone, at any time, on any document. All comments are managed according to the consensus process by a committee of experts.

## Appeal Process

When it is believed that an objection has not been adequately considered and responded to, the process for appeal, documented in the CLSI *Standards Development Policies and Processes*, is followed.

All comments and responses submitted on draft and published documents are retained on file at CLSI and are available upon request.

## Get Involved—Volunteer!

Do you use CLSI documents in your workplace? Do you see room for improvement? Would you like to get involved in the revision process? Or maybe you see a need to develop a new document for an emerging technology? CLSI wants to hear from you. We are always looking for volunteers. By donating your time and talents to improve the standards that affect your own work, you will play an active role in improving public health across the globe.

For additional information on committee participation or to submit comments, contact CLSI.

Clinical and Laboratory Standards Institute

575 West Valley Road, Suite 2500

Wayne, PA 19087 USA

T: +1.610.688.0100

F: +1.610.688.0700

[www.clsi.org](http://www.clsi.org)

[standard@clsi.org](mailto:standard@clsi.org)

# Assessment of Equivalence or Suitability of Specimen Types for Medical Laboratory Measurement Procedures

Nils B. Person, PhD, FAACC  
Karafa SW Badjie, MS, MLS(ASCP)SBB, RT(CSMLS)  
Abdel-Baset Halim, PharmD, PhD, DABCC  
Kenneth Hoekstra, PhD, HCLD, FAACC

Marina V. Kondratovich, PhD  
Qing H. Meng, PhD, MD, DABCC, FAACC  
Victoria Petrides, MS  
Richard Pfeltz, PhD

## Abstract

Clinical and Laboratory Standards Institute guideline EP35—*Assessment of Equivalence or Suitability of Specimen Types for Medical Laboratory Measurement Procedures* provides information for assessing clinically equivalent performance for additional similar-matrix specimen types and suitable performance for dissimilar-matrix specimen types. During development, medical laboratory measurement procedures are typically validated for the most common specimen type. However, it can be clinically useful to test the measurand in multiple specimen types, including different fluids (eg, serum, plasma, whole blood, urine, cerebrospinal fluid, saliva), anticoagulants, and collection devices. By following the recommendations in this guideline, developers of laboratory measurement procedures do not necessarily need to repeat the full measurement procedure validation for each specimen type. EP35 applies to both quantitative measurement procedures and qualitative examinations. This guideline is useful to developers of commercial and laboratory-developed tests and medical laboratory personnel.

Clinical and Laboratory Standards Institute (CLSI). *Assessment of Equivalence or Suitability of Specimen Types for Medical Laboratory Measurement Procedures*. 1st ed. CLSI guideline EP35 (ISBN 978-1-68440-062-1 [Print]; ISBN 978-1-68440-063-8 [Electronic]). Clinical and Laboratory Standards Institute, 950 West Valley Road, Suite 2500, Wayne, Pennsylvania 19087 USA, 2019.

The Clinical and Laboratory Standards Institute consensus process, which is the mechanism for moving a document through two or more levels of review by the health care community, is an ongoing process. Users should expect revised editions of any given document. Because rapid changes in technology may affect the procedures, methods, and protocols in a standard or guideline, users should replace outdated editions with the current editions of CLSI documents. Current editions are listed in the CLSI catalog and posted on our website at [www.clsi.org](http://www.clsi.org).

**If you or your organization is not a member and would like to become one, or to request a copy of the catalog, contact us at:**

**P:** +1.610.688.0100 **F:** +1.610.688.0700 **E:** [customerservice@clsi.org](mailto:customerservice@clsi.org) **W:** [www.clsi.org](http://www.clsi.org)

Copyright ©2019 Clinical and Laboratory Standards Institute. Except as stated below, any reproduction of content from a CLSI copyrighted standard, guideline, derivative product, or other material requires express written consent from CLSI. All rights reserved. Interested parties may send permission requests to [permissions@clsi.org](mailto:permissions@clsi.org).

CLSI hereby grants permission to each individual member or purchaser to make a single reproduction of this publication for use in its laboratory procedures manual at a single site. To request permission to use this publication in any other manner, e-mail [permissions@clsi.org](mailto:permissions@clsi.org).

## Suggested Citation

CLSI. *Assessment of Equivalence or Suitability of Specimen Types for Medical Laboratory Measurement Procedures*. 1st ed. CLSI guideline EP35. Wayne, PA: Clinical and Laboratory Standards Institute; 2019.

ISBN 978-1-558-68440-062-1 (Print)

ISBN 978-1-558-68440-063-8 (Electronic)

ISSN 1558-6502 (Print)

ISSN 2162-2914 (Electronic)

Volume 39, Number 13

# Committee Membership

## Consensus Council

**Dennis J. Ernst, MT(ASCP),  
NCPT(NCCT)  
Chairholder  
Center for Phlebotomy Education  
USA**

**Mary Lou Gantzer, PhD, FACB  
Vice-Chairholder  
USA**

J. Rex Astles, PhD, FACB, DABCC  
Centers for Disease Control and  
Prevention  
USA

Thomas R. Fritsche, MD, PhD, FCAP,  
FIDSA  
Marshfield Clinic  
USA

Loralie J. Langman, PhD, DABCC,  
FACB, F-ABFT  
Mayo Clinic  
USA

Michelle McLean, MS, MT(ASCP)  
Greiner Bio-One, Inc.  
USA

Tania Motschman, MS, MT(ASCP)SBB  
Laboratory Corporation of America  
USA

James R. Petisce, PhD  
BD Diagnostic Systems  
USA

Robert Rej, PhD  
New York State Department  
of Health – Wadsworth Center  
USA

Zivana Tezak, PhD  
FDA Center for Devices and  
Radiological Health  
USA

## Document Development Committee on Equivalency of Specimen Types for Clinical Laboratory Methods

**Nils B. Person, PhD, FAACC  
Chairholder  
Siemens Healthineers  
USA**

Karafa SW Badjie, MS, MLS(ASCP)SBB,  
RT(CSMLS)  
Mayo Clinic  
USA

Abdel-Baset Halim, PharmD, PhD,  
DABCC  
Celldex Therapeutics  
USA

Kenneth Hoekstra, PhD, HCLD, FAACC  
PeaceHealth Laboratories  
USA

Marina V. Kondratovich, PhD  
FDA Center for Devices and  
Radiological Health  
USA

Qingxin Meng, PhD, MD, DABCC,  
FAACC  
The University of Texas M.D.  
Anderson Cancer Center  
USA

Victoria Petrides, MS  
Abbott Laboratories  
USA

Richard Pfeltz, PhD  
BD Life Sciences – Diagnostic Systems  
USA

## Staff

Clinical and Laboratory Standards  
Institute  
USA

Nisha N. Fernandes, MBA, MS  
*Project Manager*

Megan L. Tertel, MA, ELS  
*Editorial Manager*

Catherine E.M. Jenkins  
*Editor*

Kristy L. Leirer, MS  
*Editor*

Laura Martin  
*Editor*

**Expert Panel on Evaluation Protocols**

**James H. Nichols, PhD, DABCC, FAACB**  
**Chairholder**  
**Vanderbilt University School of**  
**Medicine**  
**USA**

**Paula Ladwig, MS, MT(ASCP)**  
**Vice-Chairholder**  
**Mayo Clinic**  
**USA**

Valeria L. Alcon, PhD  
Health Canada  
Canada

Julianne Cook Botelho, PhD  
Centers for Disease Control and  
Prevention  
USA

Jeffrey R. Budd, PhD  
Beckman Coulter  
USA

Mark D. Kellogg, PhD, MT(ASCP),  
DABCC, FAACC  
Boston Children's Hospital  
USA

Marina V. Kondratovich, PhD  
FDA Center for Devices and  
Radiological Health  
USA

Robert J. McEnroe, PhD  
USA

Jeffrey E. Vaks, PhD  
Roche Molecular Diagnostic  
USA

# Contents

Abstract	i
Committee Membership	iii
Foreword	vi
<b>Chapter 1: Introduction</b>	<b>1</b>
1.1 Scope	2
1.2 Background	2
1.3 Standard Precautions	3
1.4 Terminology	4
<b>Chapter 2: Protocol Overview</b>	<b>7</b>
2.1 Equivalence Protocol Overview	8
2.2 Establishing Specimen Equivalence or Suitability Process Flow Charts	9
<b>Chapter 3: Evaluation Plan Development</b>	<b>13</b>
3.1 Risk Assessment	14
3.2 Evaluation Plan Content	14
3.3 Acceptance Criteria	15
<b>Chapter 4: Experimental Protocols</b>	<b>17</b>
4.1 Similar Specimen Type Experimental Protocol	18
4.2 Dissimilar Specimen Type Experimental Protocol	36
4.3 Specimen Transport and Stability	37
<b>Chapter 5: Reporting of Claims in Product Labeling</b>	<b>39</b>
<b>Chapter 6: Conclusion</b>	<b>43</b>
<b>Chapter 7: Supplemental Information</b>	<b>45</b>
<b>References</b>	46
<b>Appendix A.</b> Worked Example of a Quantitative Measurement Procedure, Plasma vs Serum	48
<b>Appendix B.</b> Worked Example of a Qualitative Examination, Plasma vs Serum	60
<b>Appendix C.</b> Calculating Confidence Intervals for Standard Deviation Ratios	66
<b>The Quality Management System Approach</b>	68
<b>Related CLSI Reference Materials</b>	70

## Foreword

For measurement procedures whose performance characteristics have previously been validated with a primary specimen type, this guideline provides recommendations for assessing clinically equivalent performance for other similar-matrix specimen types and suitable performance for dissimilar-matrix specimen types. These assessments provide verification options that do not repeat full measurement procedure validation for the additional specimen types, which include different fluids (eg, serum, plasma, whole blood, urine, cerebrospinal fluid, saliva), anticoagulants (eg, EDTA, citrate, oxalate), and collection devices (eg, gel barrier, plain tube). To date, there is no general guidance on requirements or protocols for demonstrating multiple specimen type equivalence or suitability for use on measurement procedure performance. Multiple sources provide guidance (eg, anticoagulant testing in CLSI document EP07,<sup>1</sup> discussion of alternate body fluids in CLSI document C49,<sup>2</sup> specimen collection tube evaluation in CLSI document GP34<sup>3</sup>), but the CLSI documents provide the information as a cohesive whole. EP35 provides guidance on verifying clinically equivalent or suitable performance for additional specimen types without necessarily having to repeat the full measurement procedure validation for each specimen type. EP35 applies to both quantitative measurement procedures and qualitative examinations and is useful to developers of commercial and laboratory-developed tests and medical laboratory personnel.

Because measurement procedure performance characteristics can change when specimen types have substantially different matrix characteristics, evaluation of performance often needs to be based on suitability of the observed performance to the clinical requirements for the specific specimen type matrix rather than strict numerical equivalence. Therefore, access to the necessary clinical information is key to establishing equivalent or suitable performance for multiple specimen types, including the expected interval of measurand concentrations, inherent biological variability, medical decision levels, and any other relevant information for each specimen type. These characteristics can vary considerably between specimen types for the same measurand (eg, creatinine in serum vs urine). Once the necessary clinical information is available, the desirable measurement procedure performance attributes can be characterized for each specimen type based on risk assessment. After the performance requirements are established for each specimen type, the protocols described in this guideline can be used to document clinically equivalent or suitable performance.

**NOTE:** The content of this guideline is supported by the CLSI consensus process and does not necessarily reflect the views of any single individual or organization.

### KEY WORDS

Candidate specimen type

Equivalence

Suitable

Clinical equivalence

Primary specimen type

Clinical suitability


Specimen type

# Chapter 1

## Introduction

This chapter includes:

- Guideline's scope and applicable exclusions
- Background information pertinent to the guideline's content
- Standard precautions information
- "Note on Terminology" that highlights particular use and/or variation in use of terms and/or definitions
- Terms and definitions used in the guideline
- Abbreviations and acronyms used in the guideline



# Assessment of Equivalence or Suitability of Specimen Types for Medical Laboratory Measurement Procedures

## 1 Introduction

### 1.1 Scope

This guideline provides a protocol for assessing equivalence or suitability for use of a different specimen type compared with the established primary specimen type for a medical laboratory measurement procedure or qualitative examination. This guideline provides a general framework for studies that establish equivalence among similar-matrix specimen types and clinical suitability among dissimilar-matrix specimen types. It also includes instructions for laboratory verification of alternate specimen types for commercial measurement procedures. This guideline applies to both quantitative measurement procedures and qualitative examinations. The intended users of this guideline are manufacturers, developers of medical laboratory measurement procedures, and laboratorians verifying alternate specimen types.

EP35 is intended to be used for specimen types for which the desired measurand has a known clinical indication and for which adequate clinical information is available to establish risk-based clinical performance goals. Establishing clinically based performance goals is beyond this guideline's scope.

EP35 focuses on the effect of specimen type on the analytical measurement procedure. There may also be preexamination factors between specimen types that can affect results. These differences may require additional studies to characterize their effect on the results. Such preexamination factors are outside of the scope of EP35.

### 1.2 Background

Medical laboratory measurement procedure performance characteristics are generally established and validated for use for the most commonly used specimen type for the measurand, which is designated as the primary specimen type. However, there is often a clinical need to measure the same measurand in a different specimen type (eg, urine rather than serum). Changing to a specimen type can alter both the measurement procedure performance and the performance characteristics desirable for clinical use, so it is important to document that the measurement procedure performance characteristics are clinically acceptable with the candidate specimen type.

For specimen types with a similar matrix (eg, serum and plasma), the measurement procedure's performance can be tested for equivalence among specimen types. When the matrixes are dissimilar (eg, serum and urine), it might not be possible to establish equivalence (eg, because of different measuring intervals), but the new specimen type can still be shown to be clinically acceptable or suitable for use.

To assess specimen type equivalence or suitability, a definition of what constitutes equivalent or suitable performance is needed. Typically, equivalence is defined as the condition of being equal in value, worth, function, etc. In the context of establishing specimen types' equivalence or suitability for a measurement procedure, there are two primary scenarios.